Adipotide vs Tesofensine
Head-to-head comparison of Adipotide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Adipotide | Tesofensine |
|---|---|---|
| Category | Experimental Fat Loss | Weight Loss / Reuptake Inhibitor |
| Mechanism | Adipotide has a dual-domain design. The homing peptide CKGGRAKDC binds to prohibitin on the surface of endothelial cells in white adipose tissue vasculature (prohibitin is overexpressed on fat tissue blood vessels). | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | D — Animal/Preclinical Only | C — Phase II–III Clinical Trials |
| Clinical Status | Clinical development discontinued. Preclinical only (primate proof-of-concept). No human trials conducted. | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | CRITICAL: Reversible kidney toxicity observed in all primate studies; Mechanism: prohibitin expression in kidney proximal tubule cells causes off-target damage | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~3,200 g/mol | ~397.5 g/mol |
| Half-Life | ~2-4 hours (estimated) | N/A |
Overview
Adipotide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Adipotide — Mechanism & Evidence
Adipotide (FTPP) is a chimeric peptidomimetic (MW ~3,200 g/mol) composed of a prohibitin-targeting domain (CKGGRAKDC) linked to a proapoptotic domain D(KLAKLAK)2. Clinical development was discontinued due to reversible kidney toxicity observed in primate studies.
Key claims: Rapid and significant fat loss; Selectively targets fat tissue vasculature; Improves metabolic parameters.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Adipotide focuses on Body Composition, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Adipotide: CRITICAL: Reversible kidney toxicity observed in all primate studies Mechanism: prohibitin expression in kidney proximal tubule cells causes off-target damage Elevated BUN and creatinine during treatment; reversed after discontinuation
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.